Commentary - Journal of Cancer Immunology (2022) Volume 4, Issue 1
OGR1-a Novel Modulator Target of Tumor Immunotherapy
Guoxin Zhang1,2,3, Ran Gao1,2,3*
1National Human Diseases Animal Model Resource Center, The Institute of Laboratory Animal Science, Chinese Academy of
Medical Sciences & Peking Union Medical College, Beijing, China
2NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Engineering Research Center for Experimental
Animal Models of Human Critical Diseases, Beijing, China
¤Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Beijing, Chi
- *Corresponding Author:
- Ran Gao
Received date: February 23, 2022; Accepted date: March 29, 2022
Citation: Zhang G, Gao R. OGR1-a Novel Modulator Target of Tumor Immunotherapy. J Cancer Immunol. 2022;4(1):30-32.
Copyright: © 2022 Zhang G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Tumors mainly utilize glucose to promote aerobic glycolysis for their survival (Warburg effect). The highly glycolytic environment is not suitable for the survival and function of effector T cells, and leads to the decline of antitumor immunity. A recent study by Cao et al. published in Cancer Gene Therapy showed the importance of OGR1 in modulating acidic microenvironment and enhances the function of effector CD8+ T cells. These researchers have found a new target to change the function of CD8+ T cell in acidic microenvironment of tumor, which may provide a new strategy for improving cancer immunotherapy.
Ovarian cancer G-protein-coupled receptor 1 (OGR1) is also called GPR68, an acid-sensitive receptor that responds to extracellular acidity and regulates important physiological functions, including tumor metastasis, immunity, inflammation, pH homeostasis [1-7]. OGR1 is widely expressed in a large number of cells and tissues, especially including immune cells, spleen, testis, brain, etc. [8,9]. The structure of many GPCRs usually includes one extracellular N-terminal motif, followed by seven transmembrane motifs α-Helix (I– VII), with three intracellular and three extracellular rings, and an intracellular C-terminal domain. However, so far, the crystal or low-temperature electron microscope structure of OGR1 has not been analyzed. OGR1 has been receiving increasing attention in recent years and represents a potential therapeutic target for drug design and development. Relevant many studies have also reported the different allosteric activation modes of OGR1, one through interaction with divalent metal ions at the extracellular surface , and another way, some
benzodiazepines can activate OGR1, it mainly acts as allosteric
regulator and extracellular acidic pH. However, lorazepam can
also activate OGR1 at high extracellular pH 8.0 . Yu et al. research teams have produced an improved OGR1 positive allosteric modulator through the study of structure-activity relationship, which is used to study the physiological and pathophysiological effects of OGR1 in vitro and in vivo .
Cheryl de Vallièrea et al. evaluated the effects of a novel OGR1
inhibitor in murine models of colitis . Interestingly, OGR1
also plays the role of mechanical transmission of pressure
signals, which can sense the blood flow shear stress in the
artery and regulate vascular physiology . The expression of
OGR1 in hematopoietic cells is up-regulated with age, which
leads to the increase of the number of B lymphocytes in the
process of hematopoietic regeneration .
The Role of OGR1 in Cancer
The physiological pH of blood and tissue is about pH 7.4, but in the tumor microenvironment the pH can range from 5.5 to 7.0 [16-18]. However, the complex tumor microenvironment is composed of many types of cells. In addition to malignant cells, the tumor microenvironment is composed of macrophages, cancer-related fibroblasts, endothelial cells and other immune cells. Many factors, including insufficient blood perfusion (and hypoxia), inflammation and glycolytic cell metabolism, can lead to acidic tumor microenvironment [19,20]. OGR1 is
expressed in different cell types in tumor microenvironment
and plays an important role in tumorigenesis and progression.
Pancreatic ductal adenocarcinoma cells induce the expression
of OGR1 in cancer associated fibroblasts. OGR1 can sense the
acidic microenvironment, increase the production of fibrosis
markers and IL-6, and promote the proliferation of pancreatic
ductal adenocarcinoma cells. OGR1 expressed by cancer
associated fibroblasts is a mediator of low pH promoting
tumor microenvironment, especially the interaction between
pancreatic ductal adenocarcinoma cells and cancer associated
fibroblasts. It provides a new target for the treatment of
pancreatic cancer .
The Effects of OGR1 on Immune Modulation
In a previous study, Yan et al. used through genetically engineered mice that the expression of OGR1 in bone marrowderived CD11b+ Gr1+ double positive cells is necessary for prostate cancer tumor cells to induce immunosuppression . Adoptive therapy using engineered human immune effector cells and checkpoint blocking therapy have completely changed the traditional way of tumor treatment [21,22]. Effective anti-tumor immune therapy in solid tumors relies on the presence of effector T cells [23,24]. However, direct in vivo evidence of the interaction of OGR1 with T cells in the acidic tumor microenvironment has not been reported. Recently, Cao et al. highlights the inhibition of OGR1 enhances infiltration of T lymphocytes into the tumor parenchyma and T cell antitumor immunity, which results in attenuated tumor growth . Cao et al. utilize a tumor-transplant model of the mouse melanoma cell line B16-F10 to show that tumor growth is significantly delayed in OGR1-/- mice relative to WT mice. However, the inhibition of OGR1 in B16-F10 cells did not affect the growth of tumor. These findings suggest that OGR1 plays a role in regulating tumor growth, and the contribution of OGR1 activity in vivo comes from host cells rather than tumor cells themselves. OGR1 functions in anti-tumor immunity through the following mechanisms: OGR1 inhibition (1) triggers a strong immune response signaling and (2) results in a significant increase in the number of T-cell infiltration. Therefore, infiltration of T cells is a prognostic hallmark for positive clinical outcomes and indispensable for a desired therapeutic effect of immune checkpoint inhibitors. Next, the researchers focused on the effect of OGR1 on T cells. OGR1 inhibition reactivates T cells and enhances CD8+ T-cell effector functions at acidic pH. As a molecule that inhibits the function of T cells, OGR1 help to modulate the T cell activity, such as up regulation of type I interferon. Type I IFN-mediated immune activation is one of the essential parts in the regulation of T cell-infiltration to guide tumor from ‘cold’ to ‘hot’. OGR1 determines whether it may be a drug target, and adoptive transfer with the Ogr1-/- T cell impeded tumor growth in rag2-/- tumor bearing mice, the results showed that OGR1 knockout in T cells significantly promoted its anti-tumor effect. Overall, the effects of OGR1 on the tumor acidic microenvironment remain to be clarified and could certainly have implications for the development of synergistic combinations in antitumor immunity therapy.
Drug resistance to immune checkpoint inhibitors hinders their clinical success. Therefore, it has become a driving force to find new targets to restore the function of tumor specific T cells. The GPR171 pathway suppresses T cell activation and blockade of GPR171 signaling by an antagonist promotes antitumor T cell immunity and improves immune checkpoint blockade therapies . OGR1 plays an important role in sensing the functional characteristics of effector T cells in tumor acidic microenvironment. Therefore, the sensing and inhibitory functions of Ogr1 on T-cell immunity prompted us to look at the anti-tumor effect in Ogr1-/- mice combined with PD1 inhibitor. Unpublished data shows that the combination of PD-1 inhibitors in OGR1-/- mice showed stronger antitumor effects than PD-1 inhibitors alone. Targeting Ogr1: a promising adjuvant strategy in cancer immunotherapy. OGR1 inhibitor strategy still needs to overcome its potential toxicity in order to become the target of cancer treatment in the future. Future studies will design specific inhibitors for OGR1, and the combination of PD1 inhibitors will be better transformed into clinical practice.
The author has no conflict of interest to disclose.
- Singh LS, Berk M, Oates R, Zhao Z, Tan H, Jiang Y, et al. Ovarian
cancer G protein–coupled receptor 1, a new metastasis suppressor
gene in prostate cancer. Journal of the National Cancer Institute. 2007
Sep 5; 99(17):1313-27.
- Li J, Guo B, Wang J, Cheng X, Xu Y, Sang J. Ovarian cancer G
protein coupled receptor 1 suppresses cell migration of MCF7 breast
cancer cells via a Gα 12/13-Rho-Rac1 pathway. Journal of Molecular
Signaling. 2013 Dec; 8(1):1-8.
- Damaghi M, Wojtkowiak JW, Gillies RJ. pH sensing and regulation
in cancer. Frontiers in Physiology. 2013 Dec 17; 4:370.
- Ren J, Zhang L. Effects of ovarian cancer G protein coupled receptor
1 on the proliferation, migration, and adhesion of human ovarian
cancer cells. Chinese Medical Journal. 2011 May 5; 124(09):1327-32.
- Wiley SZ, Sriram K, Liang W, Chang SE, French R, McCann T, et
al. GPR68, a proton?sensing GPCR, mediates interaction of cancerassociated
fibroblasts and cancer cells. The FASEB Journal. 2018 Mar;
- Yan L, Singh LS, Zhang L, Xu Y. Role of OGR1 in myeloid-derived
cells in prostate cancer. Oncogene. 2014 Jan; 33(2):157-64.
- Okajima F. Regulation of inflammation by extracellular
acidification and proton-sensing GPCRs. Cellular Signalling. 2013 Nov 1; 25(11):2263-71.
- Regard JB, Sato IT, Coughlin SR. Anatomical profiling of G proteincoupled
receptor expression. Cell. 2008 Oct 31; 135(3):561-71.
- Willnow TE, Andersen OM. Sorting receptor SORLA–a trafficking path to avoid Alzheimer disease. Journal of Cell Science. 2013 Jul 1;126(13):2751-60.
- Huang XP, Kenakin TP, Gu S, Shoichet BK, Roth BL. Differential
roles of extracellular histidine residues of GPR68 for proton-sensing
and allosteric modulation by divalent metal ions. Biochemistry. 2020
- Huang XP, Karpiak J, Kroeze WK, Zhu H, Chen X, Moy SS, et al.
Allosteric ligands for the pharmacologically dark receptors GPR68
and GPR65. Nature. 2015 Nov;527(7579):477-83.
- Yu X, Huang XP, Kenakin TP, Slocum ST, Chen X, Martini ML, et
al. Design, Synthesis, and Characterization of Ogerin-Based Positive
Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).
Journal of Medicinal Chemistry. 2019 Jul 12;62(16):7557-74.
- de Vallière C, Bäbler K, Busenhart P, Schwarzfischer M, Maeyashiki
C, Schuler C, et al. A Novel OGR1 (GPR68) Inhibitor Attenuates
Inflammation in Murine Models of Colitis. Inflammatory Intestinal
- Xu J, Mathur J, Vessières E, Hammack S, Nonomura K, Favre J, et
al. GPR68 senses flow and is essential for vascular physiology. Cell.
2018 Apr 19;173(3):762-75.
- He X, Feng S, Hawkins C, Lawley L, Fan W, Xu Y, et al. G proteincoupled
receptor 68 increases the number of B lymphocytes.
American Journal of Blood Research. 2020;10(2):15.
- Gatenby RA, Gillies RJ. Why do cancers have high aerobic
glycolysis?. Nature Reviews Cancer. 2004 Nov;4(11):891-9.
- Cairns R, Papandreou I, Denko N. Overcoming physiologic
barriers to cancer treatment by molecularly targeting the tumor microenvironment. Molecular Cancer Research. 2006 Feb 1;4(2):61-
- Wiley SZ, Sriram K, Salmerón C, Insel PA. GPR68: an emerging
drug target in cancer. International journal of Molecular Sciences.
- Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as
a driver of cancer. Annual Review of Physiology. 2020 Feb 10;82:103-
- Wang JX, Choi SY, Niu X, Kang N, Xue H, Killam J, et al. Lactic
acid and an acidic tumor microenvironment suppress anticancer
immunity. International Journal of Molecular Sciences. 2020
- Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM. Principles
of adoptive T cell therapy in cancer. InSeminars in Immunopathology
2019 Jan (Vol. 41, No. 1, pp. 49-58).
- Chan JD, Lai J, Slaney CY, Kallies A, Beavis PA, Darcy PK. Cellular
networks controlling T cell persistence in adoptive cell therapy.
Nature Reviews Immunology. 2021 Dec;21(12):769-84.
- Lim AR, Rathmell WK, Rathmell JC. The tumor microenvironment
as a metabolic barrier to effector T cells and immunotherapy. Elife.
2020 May 5;9:e55185.
- Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al.
Suppression of exosomal PD-L1 induces systemic anti-tumor
immunity and memory. Cell. 2019 Apr 4;177(2):414-27.
- Cao L, Li W, Yang X, Zhang W, Li M, Zhang H, et al. Inhibition of host
Ogr1 enhances effector CD8+ T-cell function by modulating acidic
microenvironment. Cancer Gene Therapy. 2021 Nov;28(10):1213-24.
- Fujiwara Y, Torphy RJ, Sun Y, Miller EN, Ho F, Borcherding N,
et al. The GPR171 pathway suppresses T cell activation and limits
antitumor immunity. Nature Communications. 2021 Oct 6;12(1):1-4.